Year: 2017

U.S. House Republicans were moving ahead on Friday with legislation aimed at dismantling Obamacare, despite concerns about not having a replacement for the healthcare program and the potential financial costs in repealing President Barack Obama's landmark law. Moderate Republican Representative Charlie Dent said he had reservations about voting for the effort to start a repeal but would not say whether he would vote for or against it. Dent and other House Republicans on Friday speculated there was enough support within their party to pass the measure instructing committees to begin writing legislation to repeal Obamacare, known formally as the Affordable Care Act.

Go to Source

The early reaction to the increased soda prices hasn't exactly been positive, and switching to diet soda offers no relief — the tax, controversially, …
Go to Source

(Reuters) – A U.S. appeals court on Thursday ruled in favor of Eli Lilly & Co in a closely-watched patent case, saying a lower court judge correctly found Teva Pharmaceutical Industries Ltd and other companies liable for inducing the infringement of Lilly's lung cancer drug Alimta. The decision by the U.S. Federal Circuit Court of Appeals came in a case in which Lilly sought to block Teva and other defendants from launching generic versions of Alimta, one of its best-selling drugs, before patent protections fully expire in 2022.

Go to Source

And one particularly extreme concept appears to have come into fashion – the "Milk Diet", where people consume ONLY milk for a month. The full …
Go to Source

WASHINGTON (Reuters) – Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push “Dermagraft,” a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.

Go to Source

Merck & Co has pulled ahead of rivals in the race to combine immunotherapy with other drugs as a treatment for lung cancer, potentially giving it a major lift in the battle for the largest cancer market. U.S. regulators have agreed to a speedy review of Merck’s application to combine its immune system-boosting drug Keytruda with chemotherapy as an initial therapy for advanced lung cancer, the U.S. drugmaker said. Merck said the U.S. Food and Drug Administration (FDA) would decide by May 10 whether to approve its Keytruda combination treatment, sending the company’s stock 5 percent higher in early U.S. trading on Wednesday.
Go to Source